Certara to Expand its Drug Discovery Software Capabilities Through the Acquisition of Chemaxon
Shots:
- Certara has entered into a definitive agreement to acquire Chemaxon, the financial details of which were undisclosed. The transaction is anticipated to conclude in H2’24, contingent upon regulatory approval and other customary closing conditions
- The acquisition will enhance Certara's drug discovery capabilities by incorporating Chemaxon's software which digitizes the design, make, test & analyze (DMTA) lifecycle for the discovery of chemical leads and further allows chemical structure drawing, property prediction & analysis
- The resulting entity will provide a complete data and predictive analytics platform, enhancing decision-making in drug development
Ref: Certara | Image: Certara
Related News:- Aurigene and Vipergen Enter into a Strategic Collaboration to Offer DEL Screening and Integrated Drug Discovery Services
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
